Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
NEE-MY2069-100ug
$360.00
NEE-MY2069-1mg (500ug X 2)
$2380.00
ETA of in-stock products:2 business days

Product Details

  • Source

    Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) is a chimeric monoclonal antibody recombinantly expressed in HEK293, which combines the variable region of a mouse monoclonal antibody with human constant domain.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    8E5

  • Isotype

    Human IgG1, Kappa

  • Host Species

    Mouse

  • Reactivity

    Influenza A virus (Victoria/2570/2019)

  • Immunogen

    Recombinant Influenza A [Victoria/2570/2019(H1N1)] Neuraminidase (NA) Protein is expressed from human 293 cells

  • Specificity

    Specifically recognizes Influenza A [Victoria/2570/2019(H1N1)] Neuraminidase (NA) Protein.

  • Cross Verification

    This product No cross-reactivity in ELISA with
    Influenza B [Austria/1359417/2021] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5245).
    Influenza B [PHUKET/3073/2013] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5246).
    Influenza A [Darwin/6/2021] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5247).
    Influenza A [Sydney/5/2021] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5248).
    Influenza A [A/Darwin/9/2021 (H3N2)] Neuraminidase (NA) Protein, His Tag (Cat. No. NE2-V5249).
    Influenza A [turkey/Germany-MV/R2472/2014(H5N8)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V5249).
    Influenza A [A/Thailand/1(KAN-1)/2004(H5N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. HA1-V5245).
    Influenza A [Guangdong/18SF020(H5N6)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524h).
    Influenza A [Wisconsin/588/2019(H1N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524k).
    Influenza A [Wisconsin/67/2022(H1N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524m).

  • Purification

    Protein A purified / Protein G purified.

  • Aggregation

    Less than 10%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Bioactivity-ELISA

     Neuraminidase (NA) ELISA

    Immobilized Influenza A [Victoria/2570/2019(H1N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524e) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) (Cat. No. NEE-MY2069) with a linear range of 0.3-5 ng/mL (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Influenza, commonly known as 'the flu', is an infectious disease of birds and mammals caused by RNA viruses of the family Orthomyxoviridae, the influenza viruses. The virus is divided into three main types (Influenzavirus A, Influenzavirus B, and Influenzavirus C), which are distinguished by differences in two major internal proteins (hemagglutinin (HA) and neuraminidase (NA), which are the most important targets for the immune system. Hemagglutinin binds to the sialic acid-containing receptors on the surface of host cells during initial infection and at the end of an infectious cycle which makes it a great target for vaccine studies.

Recent Advances

 
Drug Development Progress
  • English Name:

    Neuraminidase

  • Category:

  • Approved Drugs:

    4 Details

  • Drugs in Clinical Trials:

    10 Details

  • Highest Development Stage:

    Approved

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background